ACN - 101321555 Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)
Generic filters
Exact text matches only
Search into
Filter by Categories
Research integrity
Filter by Categories
Human Research Ethics

Resource Library

Research Ethics MonthlyAbout Us

ResourcesMerit and integrity

Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)

Will the coronavirus kill off the ‘dinosaur’ world of academic publishing? – South China Morning Post (Linda Lew | March 2020)0

Posted by Admin in on April 26, 2020

  • The deadly pandemic has brought back a long-running debate about companies profiting from the publication of research often freely supplied by the author
  • As the biggest names in the business respond to academics’ demands to bring down paywalls, new platforms are getting fresh studies out to the public

Medical researchers in Asia, Europe and the United States are working around the clock on ways to fight the Covid-19 pandemic, hunting for clues and crunching data from decades of studies on pathogens similar to the new coronavirus

The importance of that research was stressed on Friday when science authorities from 12 countries, including the US, Italy, and South Korea, released a statement urging corporate publishers of academic papers to make all relevant information openly and quickly available.

“[We] urge publishers to voluntarily agree to make their Covid-19 and coronavirus-related publications, and the available data supporting them, immediately accessible,” it said.

Read the rest of this discussion piece

(US) Federal judge rules clinical trial sponsors must publish a decade’s worth of missing data – STAT (Lev Facher | February 2020)0

Posted by Admin in on April 24, 2020

The degree to which the results of clinical trials are not reported – especially when the expected results aren’t found – is a serious problem.  It’s inefficient, because down the road another researcher may seek to do the same test, not realising that it has already been unsuccessfully tested.  It is dangerous, because researchers and clinicians may expose patients to an agent because they don’t know about the failure.

WASHINGTON — For years, government research agencies have misinterpreted a law that requires them to collect and post clinical trial data, a federal judge ruled this week, leaving behind a 10-year gap in data that now must be made publicly available.

Now, potentially hundreds of universities, drug companies, and medical device manufacturers are on the hook to release previously unpublished data. The ruling affects trials conducted for as-yet-unapproved drugs and devices in that 10-year stretch, according to a lawyer for the plaintiffs — meaning hundreds or even upwards of 1,000 noncompliant trials would be forced to post data.

The ruling, from a federal judge in New York’s Southern District, puts sponsors of clinical trials during that span out of compliance if they have not posted results to the government repository ClinicalTrials.Gov.

“This decision brings us one step closer to what federal law requires — providing the American public with complete access to clinical trial results on drugs and medical devices approved by the FDA,” said Christopher Morten, a supervising attorney at New York University’s Law & Policy Clinic who represented the plaintiffs. The ruling, he said, “makes it harder for drug companies, device manufacturers, and other trial sponsors to keep unfavorable trial results secret.”

Read the rest of this news story

Hydroxychloroquine-COVID-19 study did not meet publishing society’s “expected standard” – Retraction Watch (Adam Marcus | April 2020)0

Posted by Admin in on April 15, 2020

The paper that appears to have triggered the Trump administration’s obsession with hydroxychloroquine as a treatment for infection with the novel coronavirus has received a statement of concern from the society that publishes the journal in which the work appeared.

We suspect that sadly, the commander in tweet doesn’t read Retraction Watch.

The April 3, 2020, notice, from the International Journal of Antimicrobial Agents, states that the March 20 article, “Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non-randomized clinical trial

does not meet the [International Society of Antimicrobial Chemotherapy’s] expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.

Read the rest of this discussion piece

Sidelined by Scandal, a Top Disease Modeler Watches and Worries – UnDark (Jill Neimark | April 2020)0

Posted by Admin in on April 13, 2020

Fraud charges have upended Eva Lee’s career at a time when her talents are in high demand. Is a reprieve warranted?

ON A BALMY Georgia evening in January, Eva Lee, director of the Center for Operations Research in Medicine and Health Care at the Georgia Institute of Technology, was finishing up a paper about the global spread of avian flu and Middle East Respiratory Syndrome, or MERS. It was late and her husband was asleep next to her in the bedroom of their bungalow in a quiet Atlanta neighborhood.

This is a great article about a tricky topic.  We are planning a discussion activity sheet, inspired by this story, that will be posted to the subscribers’ area.

On a whim, she says, she had recently added the novel coronavirus to her analysis, and it changed everything.

The 55-year-old mathematician was already widely regarded for her large-scale computational algorithms and models for tackling outbreaks and natural disasters. In 2003, she began development of a software program called RealOpt, which offers detailed models for strategic planning and operational responses to outbreaks, pandemics, and national disasters based on three-dimensional geospatial information, demographic and economic data, and other variables.

Read the rest of this discussion piece